Furthermore, the compensatory activation of the PI3K-AKT and RAS–RAF-MAPK pathways have emerged as a plausible route of resistance in AML treated with TKIs such as inhibitors of FLT3, BCL2, and IDH [39]. The gene discussed is AKT1; the disease is acute myeloid leukemia.